Abbvie Inc (ABBV) Beta Value: Understanding the Market Risk

XPO

The price-to-earnings ratio for Abbvie Inc (NYSE: ABBV) is above average at 59.97x. The 36-month beta value for ABBV is also noteworthy at 0.57. There are mixed opinions on the stock, with 13 analysts rating it as a “buy,” 8 rating it as “overweight,” 10 rating it as “hold,” and 0 rating it as “sell.”

The public float for ABBV is 1.77B, and at present, short sellers hold a 1.09% of that float. The average trading volume of ABBV on December 16, 2024 was 5.91M shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

ABBV) stock’s latest price update

Abbvie Inc (NYSE: ABBV)’s stock price has plunge by -0.81relation to previous closing price of 173.37. Nevertheless, the company has seen a -2.61% plunge in its stock price over the last five trading sessions. forbes.com reported 2024-12-16 that The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. AbbVie presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most “interesting” ideas that merit further research by investors.

ABBV’s Market Performance

ABBV’s stock has fallen by -2.61% in the past week, with a monthly rise of 1.38% and a quarterly drop of -11.10%. The volatility ratio for the week is 1.78% while the volatility levels for the last 30 days are 1.95% for Abbvie Inc The simple moving average for the last 20 days is -2.03% for ABBV stock, with a simple moving average of -3.90% for the last 200 days.

Analysts’ Opinion of ABBV

Many brokerage firms have already submitted their reports for ABBV stocks, with BofA Securities repeating the rating for ABBV by listing it as a “Neutral.” The predicted price for ABBV in the upcoming period, according to BofA Securities is $191 based on the research report published on December 10, 2024 of the current year 2024.

Daiwa Securities, on the other hand, stated in their research note that they expect to see ABBV reach a price target of $180. The rating they have provided for ABBV stocks is “Neutral” according to the report published on December 05th, 2024.

Leerink Partners gave a rating of “Outperform” to ABBV, setting the target price at $206 in the report published on November 22nd of the current year.

ABBV Trading at -6.73% from the 50-Day Moving Average

After a stumble in the market that brought ABBV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.05% of loss for the given period.

Volatility was left at 1.95%, however, over the last 30 days, the volatility rate increased by 1.78%, as shares surge +4.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.46% lower at present.

During the last 5 trading sessions, ABBV fell by -2.58%, which changed the moving average for the period of 200-days by -3.85% in comparison to the 20-day moving average, which settled at $175.54. In addition, Abbvie Inc saw 10.97% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ABBV starting from Hudson Thomas J, who proposed sale 49,170 shares at the price of $189.08 back on Aug 08 ’24. After this action, Hudson Thomas J now owns shares of Abbvie Inc, valued at $9,297,210 using the latest closing price.

GONZALEZ RICHARD A, the EXECUTIVE CHAIRMAN OF BOARD of Abbvie Inc, sale 66,500 shares at $186.52 during a trade that took place back on Aug 05 ’24, which means that GONZALEZ RICHARD A is holding 446,599 shares at $12,403,580 based on the most recent closing price.

Stock Fundamentals for ABBV

Current profitability levels for the company are sitting at:

  • 0.25 for the present operating margin
  • 0.77 for the gross margin

The net margin for Abbvie Inc stands at 0.09. The total capital return value is set at 0.14. Equity return is now at value 56.06, with 3.63 for asset returns.

Based on Abbvie Inc (ABBV), the company’s capital structure generated 0.92 points at debt to capital in total, while cash flow to debt ratio is standing at 0.23. The debt to equity ratio resting at 11.78. The interest coverage ratio of the stock is 5.44.

Currently, EBITDA for the company is 17.31 billion with net debt to EBITDA at 2.63. When we switch over and look at the enterprise to sales, we see a ratio of 6.64. The receivables turnover for the company is 4.84for trailing twelve months and the total asset turnover is 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.65.

Conclusion

In summary, Abbvie Inc (ABBV) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts